Glenmark Recalls 114 Batches of Potassium Chloride
The recalled batches have been found to have potassium chloride that does not dissolve, which can cause high potassium levels that can lead to hypertension, heart failure, or renal dysfunction.
Glenmark Pharmaceuticals is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules 750 mg because of failed dissolution.
Potassium chloride that does not dissolve can cause patients to have high potassium levels, also known as hyperkalemia. This can result in irregular heartbeat that can lead to cardiac arrest. For patients with underlying comorbidities or conditions that cause altered potassium levels, such as hypertension, heart failure, or renal dysfunction, there is a possibility of developing hyperkalemia. This could lead to potential life threatening cardiac arrythmias, severe muscle weakness, and death.
In a news release, Glenmark said the company has not received any reports of hyperkalemia or serious adverse events from spontaneous sources related to this recall.
The batches being recalled have expiration dates from June 2024 to September 2025. A list of the products with NDC and batch numbers can be found here.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
